Anti-NHS monoclonal antibody

Pre-made anti-NHS monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to NHS/NHS products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2626-Ab-1/ GM-Tg-hg-IP2626-Ab-2Anti-Human NHS monoclonal antibodyHuman
GM-Tg-rg-IP2626-Ab-1/ GM-Tg-rg-IP2626-Ab-2Anti-Rat NHS monoclonal antibodyRat
GM-Tg-mg-IP2626-Ab-1/ GM-Tg-mg-IP2626-Ab-2Anti-Mouse NHS monoclonal antibodyMouse
GM-Tg-cynog-IP2626-Ab-1/ GM-Tg-cynog-IP2626-Ab-2Anti-Cynomolgus/ Rhesus macaque NHS monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2626-Ab-1/ GM-Tg-felg-IP2626-Ab-2Anti-Feline NHS monoclonal antibodyFeline
GM-Tg-cang-IP2626-Ab-1/ GM-Tg-cang-IP2626-Ab-2Anti-Canine NHS monoclonal antibodyCanine
GM-Tg-bovg-IP2626-Ab-1/ GM-Tg-bovg-IP2626-Ab-2Anti-Bovine NHS monoclonal antibodyBovine
GM-Tg-equg-IP2626-Ab-1/ GM-Tg-equg-IP2626-Ab-2Anti-Equine NHS monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2626-Ab-1/ GM-Tg-hg-IP2626-Ab-2; GM-Tg-rg-IP2626-Ab-1/ GM-Tg-rg-IP2626-Ab-2;
GM-Tg-mg-IP2626-Ab-1/ GM-Tg-mg-IP2626-Ab-2; GM-Tg-cynog-IP2626-Ab-1/ GM-Tg-cynog-IP2626-Ab-2;
GM-Tg-felg-IP2626-Ab-1/ GM-Tg-felg-IP2626-Ab-2; GM-Tg-cang-IP2626-Ab-1/ GM-Tg-cang-IP2626-Ab-2;
GM-Tg-bovg-IP2626-Ab-1/ GM-Tg-bovg-IP2626-Ab-2; GM-Tg-equg-IP2626-Ab-1/ GM-Tg-equg-IP2626-Ab-2
Products NameAnti-NHS monoclonal antibody
Formatmab
Target NameNHS
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-NHS monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2626-Ag-1Recombinant multi-species NHS/ CTRCT40/ CXN protein


    Target information

    Target IDGM-IP2626
    Target NameNHS
    Gene ID4810,195727,317494,714180,491757,101098928,539895,100051387
    Gene Symbol and SynonymsCTRCT40,CXN,Gm389,Gm48,NHS,Nhs1,RGD1561818,SCML1,Xcat
    Uniprot AccessionQ6T4R5
    Uniprot Entry NameNHS_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188158
    Target ClassificationN/A

    The target: NHS, gene name: NHS, also named as CTRCT40, CXN, SCML1. This gene encodes a protein containing four conserved nuclear localization signals. The encoded protein functions in eye, tooth, craniofacial and brain development, and it can regulate actin remodeling and cell morphology. Mutations in this gene have been shown to cause Nance-Horan syndrome, and also X-linked cataract-40. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, May 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.